News

Posts are organized into categories for ease of navigation:

  • Database release

    Added entries:

    • (FDA) RET somatic variants associated with sensitivity to pralsetinib in advanced or metastatic medullary thyroid cancer.
    • (FDA) RET fusions associated with sensitivity to pralsetinib in advanced or metastatic thyroid cancer.
    • (Inferential) CDK274 amplifications associated with sensitivity to chemotherapy in combination with pembrolizumab in locally recurrent or metastatic triple-negative breast cancer.
    Continue reading
  • Database release

    This release focuses on FDA approvals since March 2020. In addition to the following changes, the citation style for all FDA approved associated have been updated to match American Medical Association (AMA) style formatting.

    Continue reading